CABG Beats DES In SYNTAX Trial; Observers Expect Little Change In Practice

Analysts and physicians predict one-year results from the SYNTAX trial will have little short-term impact on demand for drug-eluting stents, even though the devices performed worse than coronary artery bypass graft (CABG) surgery in this seminal randomized trial